Join the Oncology Voice Network. Join for Free
Aspiring MSL Insights: Acing Behavioral Based Job Interviews

Aspiring MSL Insights: Acing Behavioral Based Job Interviews


Share This Article


Aspiring MSL Insights: Acing Behavioral Based Job Interviews 🎯💼

👉 If you’re an aspiring MSL going into your first MSL interview, you should be preparing for #BehavioralBased #JobInterview #Questions. What are those?

👉 Michael Pietrack, the Medical Affairs recruiting lead at Kaye/Bassman International and the host of the Pharmaverse podcast, answers the question for you in this short video.

👉 A behavioral-based style interview is one that focuses on how you've handled situations in the past, rather than just discussing your skills or qualifications in theory. The idea behind this style of interviewing is that past behavior is the best predictor of future behavior. During these interviews, you'll be asked to provide specific examples from your previous work or life experiences to demonstrate how you handled certain situations, challenges, or tasks.

👉 These types of questions are easy to spot, they generally start with one of these three phrases: 👉 "Tell me about a time when..." 👉 "Give me an example of..." 👉 "Describe a situation where..."

👉 Here’s what to do: Use concrete examples rather than hypothetical answers, and keep your responses between 1-2 minutes in length. ⏱️

👉 One way to help your answer from being long and tangential is using the STAR model to structure your responses. 🌟

📗 STAR Model:

◾ (S) Situation: Describe the context or challenge, but don’t spend too much time or add more detail than necessary.

◾ (T) Task: Explain the task or goal you were working toward. This should be one sentence.

◾ (A) Action: This is the most important point. Detail the specific actions you took to address the situation.

◾ (R) Result: Share the outcomes or results of your actions. This could also be one sentence.

Follow that model when answering, and you’ll look like a pro in your MSL interview. 🏆

Watch on YouTube

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
MSL Career Options: The transition from Field Medical to Medical Director
Partner Avatar MSL Talk: Tom Caravela, Josh Corriveau

MSL Career Options: The transition from Field Medical to Medical Director

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
OVN Avatar Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Article
External control arms in oncology: current use and future directions
OVN Avatar P.S. Mishra-Kalyani, L. Amiri Kordestani, D.R. Rivera, H. Singh, A. Ibrahim, R.A. DeClaro, Y. Shen, S. Tang, R. Sridhara, P.G. Kluetz, J. Concato, R. Pazdur, J.A. Beaver

External control arms in oncology: current use and future directions

Article
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions
OVN Avatar Charles L. Bennett , Sumimasa Nagai , Andrew C. Bennett , Shamia Hoque , Chadi Nabhan , Martin W. Schoen , William J. Hrushesky , Stefano Luminari , Paul Ray , Paul R. Yarnold , Bart Witherspoon , Josh Riente , Laura Bobolts , John Brusk , Rebecca Tombles

The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions

Explore OVN